Baidu
map

ASH19:CC-486可显著提高AML患者的总生存率

2019-12-11 Allan MedSci原创

百时美施贵宝公司的报道,在III期QUAZAR AML-001研究中,与安慰剂相比,实验药物CC-486显著提高了急性髓性白血病(AML)患者的总生存率(OS),且完全缓解(CR)较高。

百时美施贵宝公司的报道,在IIIQUAZAR AML-001研究中,与安慰剂相比,实验药物CC-486显著提高了急性髓性白血病AML)患者的总生存率(OS),且完全缓解(CR)较高。在美国血液学会(ASH)年会上发表的结果显示,在中位随访41.2个月时,CC-486组的OS24.7个月,而安慰剂为14.8个月。

根据Bristol-Myers Squibb的说法,在进行强化诱导化疗后,有81%的患者获得了CR19%的受试者获得了CR。然后,这些患者每天接受一次CC-486或安慰剂,再加上最佳的支持治疗。


原始出处:

http://www.firstwordpharma.com/node/1686792#axzz67lHrfPJs

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1649715, encodeId=7e601649e15fb, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Apr 22 13:47:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256734, encodeId=daf51256e347e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301291, encodeId=54851301291c3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595633, encodeId=e046159563378, content=<a href='/topic/show?id=147b419279' target=_blank style='color:#2F92EE;'>#CC-486#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4192, encryptionId=147b419279, topicName=CC-486)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ba18278821, createdName=日月, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=)]
    2020-04-22 tidiq
  2. [GetPortalCommentsPageByObjectIdResponse(id=1649715, encodeId=7e601649e15fb, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Apr 22 13:47:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256734, encodeId=daf51256e347e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301291, encodeId=54851301291c3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595633, encodeId=e046159563378, content=<a href='/topic/show?id=147b419279' target=_blank style='color:#2F92EE;'>#CC-486#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4192, encryptionId=147b419279, topicName=CC-486)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ba18278821, createdName=日月, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1649715, encodeId=7e601649e15fb, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Apr 22 13:47:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256734, encodeId=daf51256e347e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301291, encodeId=54851301291c3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595633, encodeId=e046159563378, content=<a href='/topic/show?id=147b419279' target=_blank style='color:#2F92EE;'>#CC-486#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4192, encryptionId=147b419279, topicName=CC-486)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ba18278821, createdName=日月, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=)]
    2019-12-13 kksonne
  4. [GetPortalCommentsPageByObjectIdResponse(id=1649715, encodeId=7e601649e15fb, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Apr 22 13:47:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256734, encodeId=daf51256e347e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301291, encodeId=54851301291c3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595633, encodeId=e046159563378, content=<a href='/topic/show?id=147b419279' target=_blank style='color:#2F92EE;'>#CC-486#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4192, encryptionId=147b419279, topicName=CC-486)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1ba18278821, createdName=日月, createdTime=Fri Dec 13 01:47:00 CST 2019, time=2019-12-13, status=1, ipAttribution=)]
    2019-12-13 日月

相关资讯

CLIN CANCER RES:CC-486治疗复发或耐药实体瘤

CC-486是阿扎胞苷口服剂,一种低甲基化药物。CLIN CANCER RES近期发表了一篇文章,报道了CC-486单药或联合细胞毒性药物卡铂或蛋白结合型紫杉醇治疗晚期不可切除的实体瘤患者的安全性和耐受性。

Baidu
map
Baidu
map
Baidu
map